Myelosuppression Die Behandlung mit Tasigna ist mit Thrombozytopenie, Neutropenie und Anämie assoziiert (National Cancer Institute Common Toxicity Criteria Grad 3-4).
Myelosuppression Treatment with Tasigna is associated with (National Cancer Institute Common Toxicity Criteria grade 3-4) thrombocytopenia, neutropenia and anaemia.